Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vesicular Monoamine Transport Proteins | 33 | 2024 | 47 | 7.510 |
Why?
|
Sesquiterpenes | 34 | 2021 | 90 | 7.380 |
Why?
|
Receptors, Nicotinic | 47 | 2018 | 76 | 7.110 |
Why?
|
Lobeline | 34 | 2024 | 40 | 6.890 |
Why?
|
Antineoplastic Agents | 34 | 2021 | 1172 | 6.770 |
Why?
|
Indoles | 33 | 2020 | 278 | 6.570 |
Why?
|
Nicotinic Antagonists | 38 | 2018 | 46 | 6.240 |
Why?
|
Dopamine | 43 | 2024 | 171 | 5.580 |
Why?
|
Structure-Activity Relationship | 63 | 2021 | 394 | 4.560 |
Why?
|
Nicotine | 38 | 2018 | 186 | 4.260 |
Why?
|
Molecular Structure | 54 | 2021 | 297 | 4.040 |
Why?
|
Rats | 92 | 2024 | 3300 | 3.160 |
Why?
|
Drug Screening Assays, Antitumor | 25 | 2021 | 136 | 2.990 |
Why?
|
Quaternary Ammonium Compounds | 15 | 2011 | 27 | 2.880 |
Why?
|
Animals | 156 | 2024 | 13150 | 2.760 |
Why?
|
Quinuclidines | 13 | 2020 | 40 | 2.740 |
Why?
|
Aza Compounds | 9 | 2020 | 14 | 2.640 |
Why?
|
Cell Line, Tumor | 43 | 2021 | 1402 | 2.590 |
Why?
|
Prodrugs | 18 | 2014 | 32 | 2.560 |
Why?
|
NF-kappa B | 19 | 2021 | 314 | 2.510 |
Why?
|
Stilbenes | 7 | 2018 | 62 | 2.430 |
Why?
|
Dose-Response Relationship, Drug | 45 | 2021 | 1374 | 2.420 |
Why?
|
Morphine Derivatives | 6 | 2021 | 29 | 2.310 |
Why?
|
Naltrexone | 19 | 2018 | 58 | 2.260 |
Why?
|
Cell Proliferation | 23 | 2021 | 1007 | 2.140 |
Why?
|
Drug Design | 13 | 2020 | 120 | 2.030 |
Why?
|
Radiation-Sensitizing Agents | 14 | 2020 | 53 | 2.010 |
Why?
|
Piperidines | 6 | 2020 | 97 | 1.910 |
Why?
|
Picolines | 14 | 2018 | 15 | 1.850 |
Why?
|
Methamphetamine | 20 | 2024 | 200 | 1.840 |
Why?
|
Morphine | 7 | 2021 | 102 | 1.820 |
Why?
|
Leukemia, Myeloid, Acute | 9 | 2016 | 183 | 1.690 |
Why?
|
Nicotinic Agonists | 15 | 2018 | 55 | 1.670 |
Why?
|
Rats, Sprague-Dawley | 52 | 2024 | 1595 | 1.630 |
Why?
|
Membrane Transport Proteins | 8 | 2010 | 49 | 1.560 |
Why?
|
Blood-Brain Barrier | 9 | 2010 | 48 | 1.560 |
Why?
|
Dopamine Uptake Inhibitors | 8 | 2019 | 55 | 1.540 |
Why?
|
Alkaloids | 4 | 2021 | 32 | 1.530 |
Why?
|
Crystallography, X-Ray | 18 | 2012 | 147 | 1.490 |
Why?
|
Molecular Docking Simulation | 10 | 2021 | 73 | 1.470 |
Why?
|
Binding Sites | 18 | 2021 | 377 | 1.460 |
Why?
|
Drug Delivery Systems | 12 | 2014 | 136 | 1.450 |
Why?
|
Tobacco Use Disorder | 8 | 2018 | 168 | 1.420 |
Why?
|
Receptor, Cannabinoid, CB1 | 6 | 2020 | 125 | 1.400 |
Why?
|
Tetrabenazine | 7 | 2015 | 12 | 1.380 |
Why?
|
Esters | 6 | 2017 | 22 | 1.380 |
Why?
|
Humans | 126 | 2024 | 49827 | 1.370 |
Why?
|
Ligands | 21 | 2020 | 204 | 1.320 |
Why?
|
Barbiturates | 7 | 2020 | 17 | 1.300 |
Why?
|
Receptor, Cannabinoid, CB2 | 4 | 2020 | 58 | 1.280 |
Why?
|
Piperazines | 5 | 2024 | 117 | 1.250 |
Why?
|
Protein Binding | 26 | 2020 | 660 | 1.250 |
Why?
|
Models, Molecular | 15 | 2020 | 337 | 1.220 |
Why?
|
Analgesics, Opioid | 8 | 2018 | 532 | 1.190 |
Why?
|
Stereoisomerism | 20 | 2016 | 104 | 1.170 |
Why?
|
Pyrimidines | 4 | 2018 | 191 | 1.160 |
Why?
|
Thiophenes | 5 | 2015 | 36 | 1.140 |
Why?
|
Analgesics | 5 | 2016 | 101 | 1.140 |
Why?
|
Cell Survival | 7 | 2016 | 598 | 1.130 |
Why?
|
Neurons | 10 | 2013 | 459 | 1.130 |
Why?
|
Triazoles | 2 | 2018 | 107 | 1.100 |
Why?
|
Pyridines | 6 | 2015 | 130 | 1.030 |
Why?
|
Hematologic Neoplasms | 2 | 2017 | 99 | 0.990 |
Why?
|
Pyridinium Compounds | 7 | 2018 | 19 | 0.970 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2015 | 69 | 0.970 |
Why?
|
Smoking | 8 | 2014 | 510 | 0.950 |
Why?
|
Carboxylic Acids | 2 | 2017 | 17 | 0.940 |
Why?
|
Pain | 8 | 2017 | 380 | 0.940 |
Why?
|
Nuclear Proteins | 5 | 2020 | 243 | 0.940 |
Why?
|
Amphetamine-Related Disorders | 10 | 2018 | 94 | 0.930 |
Why?
|
Antitubercular Agents | 5 | 2011 | 106 | 0.920 |
Why?
|
Quantitative Structure-Activity Relationship | 5 | 2013 | 32 | 0.910 |
Why?
|
Amyloid beta-Peptides | 2 | 2021 | 69 | 0.900 |
Why?
|
Pancreatic Neoplasms | 8 | 2018 | 213 | 0.880 |
Why?
|
Male | 85 | 2024 | 25093 | 0.870 |
Why?
|
Brain | 17 | 2021 | 1309 | 0.860 |
Why?
|
Narcotic Antagonists | 10 | 2018 | 130 | 0.860 |
Why?
|
Peptide Fragments | 2 | 2021 | 216 | 0.860 |
Why?
|
Acetonitriles | 2 | 2016 | 7 | 0.850 |
Why?
|
Chromatography, High Pressure Liquid | 10 | 2017 | 349 | 0.840 |
Why?
|
Smoking Cessation | 7 | 2018 | 299 | 0.840 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 8 | 2018 | 43 | 0.840 |
Why?
|
Guanidines | 3 | 2013 | 31 | 0.830 |
Why?
|
Pyrrolidines | 3 | 2013 | 83 | 0.810 |
Why?
|
Acrylonitrile | 3 | 2007 | 3 | 0.800 |
Why?
|
Molecular Conformation | 12 | 2012 | 67 | 0.800 |
Why?
|
Skin Absorption | 15 | 2014 | 22 | 0.790 |
Why?
|
Receptors, Opioid, delta | 4 | 2018 | 26 | 0.790 |
Why?
|
Tryptophan | 3 | 2011 | 99 | 0.790 |
Why?
|
Benzylamines | 1 | 2021 | 15 | 0.790 |
Why?
|
Cholinesterase Inhibitors | 1 | 2021 | 26 | 0.780 |
Why?
|
Thiazoles | 2 | 2014 | 51 | 0.770 |
Why?
|
Oocytes | 7 | 2014 | 74 | 0.770 |
Why?
|
Cotinine | 3 | 2008 | 22 | 0.760 |
Why?
|
Enzyme Inhibitors | 8 | 2019 | 391 | 0.760 |
Why?
|
Naphthalenes | 3 | 2019 | 121 | 0.750 |
Why?
|
Drug Discovery | 4 | 2021 | 85 | 0.750 |
Why?
|
Chelating Agents | 2 | 2020 | 27 | 0.750 |
Why?
|
Neuroprotective Agents | 2 | 2021 | 105 | 0.750 |
Why?
|
Chemistry, Pharmaceutical | 8 | 2009 | 32 | 0.740 |
Why?
|
Receptors, Opioid, mu | 3 | 2018 | 46 | 0.740 |
Why?
|
Oxyquinoline | 1 | 2020 | 8 | 0.740 |
Why?
|
Psychotropic Drugs | 2 | 2011 | 77 | 0.730 |
Why?
|
Kinetics | 12 | 2017 | 626 | 0.730 |
Why?
|
Imidazolidines | 2 | 2010 | 3 | 0.730 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 115 | 0.720 |
Why?
|
Oxycodone | 2 | 2012 | 27 | 0.700 |
Why?
|
Anti-Bacterial Agents | 3 | 2015 | 743 | 0.690 |
Why?
|
Hydrogen Bonding | 9 | 2012 | 31 | 0.680 |
Why?
|
Canavanine | 4 | 2003 | 4 | 0.670 |
Why?
|
Aconitine | 8 | 2015 | 9 | 0.670 |
Why?
|
Chitosan | 2 | 2011 | 32 | 0.670 |
Why?
|
Heart Diseases | 1 | 2021 | 208 | 0.650 |
Why?
|
Tetrazoles | 1 | 2018 | 41 | 0.640 |
Why?
|
Hydrazones | 2 | 2009 | 5 | 0.630 |
Why?
|
Drug Stability | 11 | 2017 | 36 | 0.630 |
Why?
|
Corpus Striatum | 14 | 2015 | 50 | 0.630 |
Why?
|
Tubulin Modulators | 2 | 2016 | 31 | 0.630 |
Why?
|
Tubulin | 2 | 2015 | 22 | 0.620 |
Why?
|
Durapatite | 2 | 2015 | 24 | 0.620 |
Why?
|
Heterocyclic Compounds | 2 | 2014 | 28 | 0.610 |
Why?
|
Self Administration | 11 | 2024 | 101 | 0.610 |
Why?
|
Synaptic Vesicles | 9 | 2015 | 20 | 0.610 |
Why?
|
Drug Carriers | 3 | 2015 | 68 | 0.600 |
Why?
|
Drug Tolerance | 9 | 2019 | 60 | 0.600 |
Why?
|
Vinyl Compounds | 2 | 2009 | 3 | 0.600 |
Why?
|
Coumarins | 2 | 2014 | 7 | 0.600 |
Why?
|
Alzheimer Disease | 1 | 2021 | 317 | 0.590 |
Why?
|
Succinates | 1 | 2017 | 3 | 0.590 |
Why?
|
Needles | 4 | 2014 | 23 | 0.590 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 5 | 2017 | 47 | 0.590 |
Why?
|
Bupropion | 5 | 2009 | 32 | 0.580 |
Why?
|
Amides | 1 | 2017 | 34 | 0.580 |
Why?
|
Thiadiazoles | 2 | 2020 | 19 | 0.570 |
Why?
|
Cell Cycle | 4 | 2014 | 232 | 0.570 |
Why?
|
Carbamates | 2 | 2014 | 16 | 0.560 |
Why?
|
Solubility | 11 | 2010 | 68 | 0.550 |
Why?
|
Dioxanes | 1 | 2016 | 10 | 0.550 |
Why?
|
Tumor Cells, Cultured | 12 | 2018 | 465 | 0.550 |
Why?
|
Molecular Targeted Therapy | 5 | 2016 | 119 | 0.550 |
Why?
|
Apoptosis | 10 | 2018 | 1100 | 0.540 |
Why?
|
Kidney Diseases | 3 | 2009 | 214 | 0.540 |
Why?
|
Hypertension | 1 | 2021 | 532 | 0.530 |
Why?
|
Brain Chemistry | 5 | 2017 | 70 | 0.530 |
Why?
|
Health Maintenance Organizations | 5 | 2014 | 15 | 0.530 |
Why?
|
Mitosis | 2 | 2014 | 92 | 0.530 |
Why?
|
Benzyl Compounds | 2 | 2006 | 3 | 0.530 |
Why?
|
Quinoxalines | 4 | 2015 | 25 | 0.530 |
Why?
|
Kidney Failure, Chronic | 6 | 2014 | 197 | 0.520 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 3 | 2013 | 126 | 0.520 |
Why?
|
Membrane Glycoproteins | 3 | 2005 | 240 | 0.520 |
Why?
|
Models, Chemical | 7 | 2009 | 66 | 0.520 |
Why?
|
Anticonvulsants | 2 | 2009 | 122 | 0.510 |
Why?
|
DNA Breaks, Double-Stranded | 6 | 2020 | 71 | 0.510 |
Why?
|
Vancomycin | 1 | 2015 | 82 | 0.500 |
Why?
|
Mecamylamine | 5 | 2010 | 13 | 0.500 |
Why?
|
Drug Evaluation, Preclinical | 10 | 2017 | 144 | 0.500 |
Why?
|
Benzodioxoles | 1 | 2016 | 56 | 0.500 |
Why?
|
DNA Cleavage | 1 | 2014 | 2 | 0.500 |
Why?
|
Guaiacol | 2 | 2005 | 2 | 0.500 |
Why?
|
Inhibitory Concentration 50 | 8 | 2019 | 76 | 0.490 |
Why?
|
Choline | 7 | 2013 | 61 | 0.490 |
Why?
|
Azetidines | 2 | 2015 | 6 | 0.490 |
Why?
|
Mice | 26 | 2020 | 5720 | 0.490 |
Why?
|
Ganglionic Stimulants | 3 | 2005 | 7 | 0.480 |
Why?
|
Angiogenesis Inhibitors | 4 | 2012 | 187 | 0.480 |
Why?
|
Osteomyelitis | 1 | 2015 | 126 | 0.480 |
Why?
|
DNA Repair | 6 | 2020 | 192 | 0.470 |
Why?
|
Excipients | 2 | 2011 | 7 | 0.460 |
Why?
|
Thiobarbiturates | 5 | 2018 | 23 | 0.440 |
Why?
|
Chlorobenzoates | 1 | 2012 | 2 | 0.430 |
Why?
|
Acetamides | 1 | 2012 | 20 | 0.420 |
Why?
|
Renal Dialysis | 4 | 2023 | 169 | 0.420 |
Why?
|
Biological Availability | 7 | 2011 | 121 | 0.410 |
Why?
|
Phosphorylation | 6 | 2021 | 536 | 0.410 |
Why?
|
Tritium | 7 | 2013 | 47 | 0.410 |
Why?
|
Protein Structure, Tertiary | 4 | 2017 | 253 | 0.400 |
Why?
|
Magnetic Resonance Spectroscopy | 7 | 2014 | 244 | 0.400 |
Why?
|
NADH, NADPH Oxidoreductases | 4 | 2016 | 12 | 0.390 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 162 | 0.390 |
Why?
|
Prostatic Neoplasms | 5 | 2017 | 396 | 0.390 |
Why?
|
Bone and Bones | 2 | 2015 | 468 | 0.380 |
Why?
|
Neoplasms | 5 | 2018 | 1233 | 0.380 |
Why?
|
Nasal Mucosa | 1 | 2011 | 19 | 0.380 |
Why?
|
Isoquinolines | 1 | 2010 | 25 | 0.380 |
Why?
|
Estrenes | 1 | 2010 | 13 | 0.380 |
Why?
|
Xenopus | 4 | 2014 | 37 | 0.380 |
Why?
|
Substance-Related Disorders | 4 | 2018 | 595 | 0.370 |
Why?
|
Administration, Cutaneous | 11 | 2014 | 49 | 0.370 |
Why?
|
Amines | 1 | 2010 | 40 | 0.370 |
Why?
|
Phosphates | 1 | 2010 | 47 | 0.370 |
Why?
|
Radioligand Assay | 5 | 2016 | 46 | 0.370 |
Why?
|
Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 1 | 0.370 |
Why?
|
Leukemia | 1 | 2011 | 65 | 0.360 |
Why?
|
Spectrometry, Fluorescence | 2 | 2009 | 45 | 0.360 |
Why?
|
Sulfonamides | 3 | 2008 | 129 | 0.360 |
Why?
|
Neurotransmitter Transport Proteins | 1 | 2009 | 1 | 0.360 |
Why?
|
Skin | 8 | 2010 | 407 | 0.350 |
Why?
|
Models, Biological | 6 | 2017 | 728 | 0.350 |
Why?
|
Reward | 3 | 2011 | 109 | 0.350 |
Why?
|
Cyclooctanes | 1 | 2009 | 2 | 0.350 |
Why?
|
Luminol | 1 | 2009 | 1 | 0.350 |
Why?
|
Dipeptides | 1 | 2009 | 21 | 0.340 |
Why?
|
Area Under Curve | 6 | 2011 | 181 | 0.340 |
Why?
|
Biphenyl Compounds | 1 | 2009 | 30 | 0.340 |
Why?
|
Pregnanolone | 2 | 2007 | 6 | 0.340 |
Why?
|
Nonlinear Dynamics | 2 | 2007 | 19 | 0.340 |
Why?
|
Isomerism | 5 | 2013 | 22 | 0.340 |
Why?
|
Insurance, Major Medical | 1 | 2009 | 2 | 0.340 |
Why?
|
Melphalan | 1 | 2010 | 174 | 0.340 |
Why?
|
Aniline Compounds | 1 | 2009 | 43 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 987 | 0.330 |
Why?
|
Estradiol | 1 | 2010 | 225 | 0.330 |
Why?
|
Drugs, Investigational | 1 | 2009 | 14 | 0.330 |
Why?
|
Fluorescent Dyes | 1 | 2009 | 101 | 0.330 |
Why?
|
Rabbits | 5 | 2016 | 370 | 0.330 |
Why?
|
Salts | 4 | 2010 | 8 | 0.330 |
Why?
|
Imidazoles | 1 | 2009 | 119 | 0.330 |
Why?
|
Oligopeptides | 1 | 2009 | 89 | 0.320 |
Why?
|
Gas Chromatography-Mass Spectrometry | 2 | 2008 | 67 | 0.320 |
Why?
|
Time Factors | 11 | 2019 | 2912 | 0.320 |
Why?
|
Chemistry Techniques, Synthetic | 2 | 2020 | 20 | 0.320 |
Why?
|
Maternal-Fetal Exchange | 1 | 2008 | 43 | 0.320 |
Why?
|
Alcohol Deterrents | 2 | 2018 | 8 | 0.320 |
Why?
|
2,2'-Dipyridyl | 2 | 2007 | 3 | 0.320 |
Why?
|
Guidelines as Topic | 1 | 2009 | 111 | 0.310 |
Why?
|
Rats, Inbred F344 | 8 | 2016 | 196 | 0.310 |
Why?
|
Pyrazoles | 3 | 2008 | 113 | 0.310 |
Why?
|
Radiation Tolerance | 6 | 2020 | 84 | 0.310 |
Why?
|
Disease Models, Animal | 10 | 2018 | 1451 | 0.310 |
Why?
|
Fentanyl | 1 | 2008 | 35 | 0.310 |
Why?
|
Female | 31 | 2021 | 26329 | 0.300 |
Why?
|
Glioblastoma | 2 | 2021 | 91 | 0.300 |
Why?
|
Tosyl Compounds | 1 | 2007 | 1 | 0.300 |
Why?
|
Drug Combinations | 4 | 2021 | 123 | 0.300 |
Why?
|
DNA-Directed DNA Polymerase | 2 | 2019 | 92 | 0.300 |
Why?
|
Bacteria | 1 | 2009 | 223 | 0.300 |
Why?
|
Benzylidene Compounds | 1 | 2007 | 4 | 0.300 |
Why?
|
Adhesives | 1 | 2007 | 2 | 0.300 |
Why?
|
gamma-Cyclodextrins | 1 | 2007 | 3 | 0.300 |
Why?
|
Transcription Factor RelA | 3 | 2021 | 29 | 0.300 |
Why?
|
Thiazines | 1 | 2007 | 3 | 0.300 |
Why?
|
beta-Cyclodextrins | 1 | 2007 | 16 | 0.290 |
Why?
|
Muscarinic Antagonists | 1 | 2007 | 21 | 0.290 |
Why?
|
Metabolic Detoxication, Phase II | 1 | 2007 | 11 | 0.290 |
Why?
|
Behavior, Addictive | 3 | 2019 | 58 | 0.290 |
Why?
|
Reproducibility of Results | 5 | 2017 | 1188 | 0.290 |
Why?
|
Small Molecule Libraries | 4 | 2018 | 68 | 0.290 |
Why?
|
Metabolic Detoxication, Phase I | 1 | 2007 | 11 | 0.290 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 91 | 0.290 |
Why?
|
Eye | 1 | 2007 | 31 | 0.290 |
Why?
|
Neurotoxicity Syndromes | 1 | 2007 | 46 | 0.280 |
Why?
|
Temperature | 1 | 2007 | 168 | 0.280 |
Why?
|
Serotonin Antagonists | 1 | 2006 | 34 | 0.280 |
Why?
|
Dihydromorphine | 1 | 2006 | 1 | 0.280 |
Why?
|
Codeine | 1 | 2006 | 6 | 0.280 |
Why?
|
Lactones | 2 | 2021 | 26 | 0.280 |
Why?
|
Sulfates | 1 | 2006 | 25 | 0.280 |
Why?
|
Formamides | 1 | 2006 | 3 | 0.270 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 152 | 0.270 |
Why?
|
Environmental Pollutants | 1 | 2007 | 91 | 0.270 |
Why?
|
Glucuronides | 2 | 2003 | 45 | 0.270 |
Why?
|
Indicators and Reagents | 2 | 2002 | 36 | 0.270 |
Why?
|
Delivery of Health Care | 1 | 2009 | 307 | 0.270 |
Why?
|
Pharmaceutical Preparations | 1 | 2006 | 76 | 0.270 |
Why?
|
Indomethacin | 1 | 2006 | 38 | 0.270 |
Why?
|
Anabasine | 1 | 2005 | 1 | 0.270 |
Why?
|
Tropanes | 1 | 2005 | 4 | 0.270 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 829 | 0.260 |
Why?
|
Boron | 1 | 2005 | 2 | 0.260 |
Why?
|
HEK293 Cells | 3 | 2024 | 222 | 0.260 |
Why?
|
Tongue | 1 | 2006 | 39 | 0.260 |
Why?
|
Biological Transport | 5 | 2010 | 173 | 0.260 |
Why?
|
Ethacrynic Acid | 1 | 2005 | 3 | 0.260 |
Why?
|
Caffeine | 2 | 2003 | 67 | 0.260 |
Why?
|
Mice, Nude | 10 | 2017 | 252 | 0.260 |
Why?
|
Membrane Transport Modulators | 1 | 2005 | 3 | 0.260 |
Why?
|
Central Nervous System | 2 | 2003 | 85 | 0.260 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 854 | 0.250 |
Why?
|
Glaucoma | 1 | 2005 | 30 | 0.250 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2005 | 102 | 0.250 |
Why?
|
Hydrazines | 1 | 2004 | 14 | 0.240 |
Why?
|
Sulfones | 1 | 2004 | 24 | 0.240 |
Why?
|
Benzoquinones | 1 | 2004 | 29 | 0.240 |
Why?
|
Cell Line | 6 | 2016 | 1002 | 0.230 |
Why?
|
Heterocyclic Compounds, 2-Ring | 1 | 2003 | 2 | 0.230 |
Why?
|
Reference Standards | 3 | 2008 | 56 | 0.230 |
Why?
|
Octanes | 1 | 2003 | 1 | 0.230 |
Why?
|
Arginine-tRNA Ligase | 1 | 2003 | 1 | 0.230 |
Why?
|
Binding, Competitive | 6 | 2011 | 95 | 0.230 |
Why?
|
Benzazepines | 3 | 2015 | 19 | 0.230 |
Why?
|
Vesicular Biogenic Amine Transport Proteins | 4 | 2008 | 4 | 0.230 |
Why?
|
Case Management | 1 | 2004 | 43 | 0.230 |
Why?
|
Blotting, Western | 5 | 2015 | 602 | 0.230 |
Why?
|
Keratinocytes | 1 | 2004 | 89 | 0.230 |
Why?
|
Central Nervous System Stimulants | 3 | 2018 | 213 | 0.230 |
Why?
|
Toxins, Biological | 1 | 2023 | 7 | 0.230 |
Why?
|
Administration, Sublingual | 3 | 2008 | 18 | 0.220 |
Why?
|
Agmatine | 1 | 2003 | 1 | 0.220 |
Why?
|
Rad51 Recombinase | 2 | 2020 | 21 | 0.220 |
Why?
|
Reactive Oxygen Species | 4 | 2018 | 408 | 0.220 |
Why?
|
Neoplasm Proteins | 2 | 2016 | 323 | 0.220 |
Why?
|
Behavior, Animal | 7 | 2016 | 182 | 0.220 |
Why?
|
Hyperalgesia | 4 | 2018 | 56 | 0.220 |
Why?
|
Linear Models | 2 | 2017 | 281 | 0.220 |
Why?
|
Models, Theoretical | 1 | 2004 | 174 | 0.210 |
Why?
|
Rats, Wistar | 2 | 2021 | 223 | 0.210 |
Why?
|
Conotoxins | 4 | 2015 | 7 | 0.210 |
Why?
|
Polyethylene Glycols | 3 | 2015 | 96 | 0.210 |
Why?
|
Chromatography, Liquid | 3 | 2008 | 232 | 0.210 |
Why?
|
Aminobutyrates | 1 | 2002 | 3 | 0.210 |
Why?
|
Cricetulus | 3 | 2017 | 97 | 0.210 |
Why?
|
Microbial Sensitivity Tests | 5 | 2016 | 271 | 0.210 |
Why?
|
Cricetinae | 4 | 2016 | 192 | 0.210 |
Why?
|
CHO Cells | 3 | 2017 | 120 | 0.200 |
Why?
|
Disease Management | 1 | 2003 | 174 | 0.200 |
Why?
|
Cannabinoids | 2 | 2020 | 105 | 0.200 |
Why?
|
Tumor Stem Cell Assay | 3 | 2016 | 17 | 0.200 |
Why?
|
Guinea Pigs | 8 | 2010 | 74 | 0.200 |
Why?
|
Locomotion | 2 | 2019 | 92 | 0.200 |
Why?
|
Electrophorus | 1 | 2021 | 5 | 0.200 |
Why?
|
Butyrylcholinesterase | 1 | 2021 | 8 | 0.200 |
Why?
|
Neoplastic Stem Cells | 2 | 2016 | 103 | 0.200 |
Why?
|
Diabetes Mellitus, Experimental | 3 | 2018 | 129 | 0.200 |
Why?
|
Mycobacterium tuberculosis | 4 | 2011 | 280 | 0.200 |
Why?
|
Acetylcholinesterase | 1 | 2021 | 19 | 0.200 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 21 | 0.200 |
Why?
|
Lung Neoplasms | 4 | 2014 | 605 | 0.200 |
Why?
|
Thermodynamics | 1 | 2021 | 34 | 0.200 |
Why?
|
Endothelium, Vascular | 3 | 2013 | 254 | 0.200 |
Why?
|
Spectrophotometry, Ultraviolet | 5 | 2008 | 32 | 0.190 |
Why?
|
Horses | 1 | 2021 | 44 | 0.190 |
Why?
|
Organoids | 1 | 2021 | 39 | 0.190 |
Why?
|
Cell Death | 3 | 2011 | 181 | 0.190 |
Why?
|
Lymphocytes | 1 | 2002 | 151 | 0.190 |
Why?
|
Cannabinoid Receptor Agonists | 2 | 2020 | 49 | 0.190 |
Why?
|
Benzene | 2 | 2011 | 6 | 0.190 |
Why?
|
DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2020 | 16 | 0.190 |
Why?
|
Hydrogen-Ion Concentration | 5 | 2009 | 174 | 0.190 |
Why?
|
Lobelia | 2 | 2011 | 2 | 0.190 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2013 | 121 | 0.190 |
Why?
|
Motor Activity | 7 | 2011 | 230 | 0.180 |
Why?
|
Least-Squares Analysis | 2 | 2013 | 43 | 0.180 |
Why?
|
Sulfuric Acids | 1 | 2020 | 8 | 0.180 |
Why?
|
Cellulose, Oxidized | 1 | 2020 | 4 | 0.180 |
Why?
|
Protein Structure, Secondary | 1 | 2020 | 72 | 0.180 |
Why?
|
Mass Spectrometry | 4 | 2014 | 306 | 0.180 |
Why?
|
Epilepsy | 1 | 2003 | 174 | 0.180 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 2014 | 29 | 0.180 |
Why?
|
Synaptosomes | 6 | 2019 | 15 | 0.180 |
Why?
|
DNA Damage | 3 | 2019 | 301 | 0.180 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2020 | 61 | 0.180 |
Why?
|
Serotonin | 3 | 2017 | 151 | 0.180 |
Why?
|
Alcohol Drinking | 2 | 2018 | 223 | 0.170 |
Why?
|
Injections, Intravenous | 4 | 2007 | 140 | 0.170 |
Why?
|
Signal Transduction | 6 | 2018 | 1617 | 0.170 |
Why?
|
Nanostructures | 1 | 2020 | 47 | 0.170 |
Why?
|
Pain Management | 2 | 2017 | 146 | 0.170 |
Why?
|
Radiation-Protective Agents | 1 | 2020 | 74 | 0.170 |
Why?
|
Vitamin E | 1 | 2020 | 81 | 0.170 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2016 | 41 | 0.160 |
Why?
|
Breast Neoplasms | 3 | 2017 | 1169 | 0.160 |
Why?
|
Aminopyrine | 1 | 2018 | 2 | 0.160 |
Why?
|
Dactinomycin | 1 | 2018 | 22 | 0.160 |
Why?
|
Growth Inhibitors | 1 | 2018 | 27 | 0.160 |
Why?
|
Blood Pressure | 1 | 2021 | 514 | 0.160 |
Why?
|
Cisplatin | 2 | 2018 | 278 | 0.160 |
Why?
|
Ethanol | 2 | 2018 | 338 | 0.160 |
Why?
|
RNA Helicases | 1 | 2018 | 29 | 0.160 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2008 | 50 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 44 | 0.160 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 56 | 0.160 |
Why?
|
Substrate Specificity | 6 | 2016 | 195 | 0.160 |
Why?
|
Hypesthesia | 1 | 2018 | 17 | 0.160 |
Why?
|
Ketamine | 2 | 2008 | 60 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 618 | 0.150 |
Why?
|
Brain Neoplasms | 1 | 2021 | 286 | 0.150 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 78 | 0.150 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2016 | 142 | 0.150 |
Why?
|
Protein Conformation | 5 | 2020 | 166 | 0.150 |
Why?
|
Analgesia | 1 | 2017 | 13 | 0.150 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2017 | 35 | 0.150 |
Why?
|
Arginine | 3 | 2003 | 179 | 0.150 |
Why?
|
I-kappa B Proteins | 1 | 2017 | 16 | 0.150 |
Why?
|
Intestinal Secretions | 1 | 2017 | 2 | 0.150 |
Why?
|
Gastric Juice | 1 | 2017 | 6 | 0.150 |
Why?
|
GTP-Binding Proteins | 1 | 2017 | 90 | 0.150 |
Why?
|
Diabetic Nephropathies | 1 | 2017 | 61 | 0.150 |
Why?
|
Diabetes Complications | 1 | 2018 | 118 | 0.140 |
Why?
|
Electrophoretic Mobility Shift Assay | 6 | 2015 | 73 | 0.140 |
Why?
|
Protein Subunits | 4 | 2015 | 77 | 0.140 |
Why?
|
Dengue Virus | 1 | 2016 | 10 | 0.140 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2016 | 33 | 0.140 |
Why?
|
Chronic Disease | 5 | 2010 | 563 | 0.140 |
Why?
|
Neoplasm Metastasis | 2 | 2015 | 231 | 0.140 |
Why?
|
Cell Division | 2 | 2011 | 292 | 0.140 |
Why?
|
Fluorouracil | 2 | 2007 | 55 | 0.140 |
Why?
|
Crystallization | 2 | 2007 | 32 | 0.140 |
Why?
|
Receptors, Opioid, kappa | 1 | 2016 | 39 | 0.140 |
Why?
|
Adenocarcinoma | 2 | 2013 | 401 | 0.140 |
Why?
|
BRCA1 Protein | 1 | 2016 | 30 | 0.140 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 114 | 0.140 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 303 | 0.130 |
Why?
|
Treatment Outcome | 5 | 2018 | 5138 | 0.130 |
Why?
|
Gliosarcoma | 1 | 2015 | 5 | 0.130 |
Why?
|
Mammary Glands, Animal | 1 | 2016 | 69 | 0.130 |
Why?
|
Dimerization | 1 | 2015 | 53 | 0.130 |
Why?
|
Debridement | 1 | 2015 | 45 | 0.130 |
Why?
|
Flow Cytometry | 4 | 2011 | 470 | 0.130 |
Why?
|
Down-Regulation | 1 | 2017 | 349 | 0.130 |
Why?
|
Oxidative Stress | 4 | 2013 | 768 | 0.130 |
Why?
|
Deoxycytidine | 2 | 2013 | 27 | 0.130 |
Why?
|
Acetylcholine | 4 | 2009 | 54 | 0.130 |
Why?
|
Breast | 1 | 2016 | 85 | 0.130 |
Why?
|
Primary Cell Culture | 1 | 2015 | 61 | 0.130 |
Why?
|
Benzothiazoles | 1 | 2015 | 6 | 0.130 |
Why?
|
Benzofurans | 1 | 2015 | 17 | 0.130 |
Why?
|
California | 3 | 2014 | 87 | 0.130 |
Why?
|
Vestibular Nerve | 1 | 2015 | 6 | 0.130 |
Why?
|
Administration, Oral | 3 | 2018 | 423 | 0.130 |
Why?
|
Receptors, Cholinergic | 1 | 2015 | 14 | 0.130 |
Why?
|
Presynaptic Terminals | 1 | 2015 | 15 | 0.130 |
Why?
|
Oxygen | 2 | 2008 | 325 | 0.130 |
Why?
|
Colchicine | 1 | 2015 | 28 | 0.130 |
Why?
|
Motor Neurons | 1 | 2015 | 39 | 0.130 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2010 | 141 | 0.130 |
Why?
|
Chronic Pain | 1 | 2017 | 161 | 0.130 |
Why?
|
HT29 Cells | 2 | 2016 | 11 | 0.120 |
Why?
|
Stem Cells | 1 | 2016 | 171 | 0.120 |
Why?
|
Glutathione | 2 | 2013 | 295 | 0.120 |
Why?
|
Antiviral Agents | 1 | 2016 | 174 | 0.120 |
Why?
|
Enzyme Assays | 1 | 2014 | 10 | 0.120 |
Why?
|
Rubidium Radioisotopes | 2 | 2006 | 4 | 0.120 |
Why?
|
Drug Synergism | 5 | 2018 | 150 | 0.120 |
Why?
|
High-Throughput Screening Assays | 1 | 2014 | 37 | 0.120 |
Why?
|
Dihydro-beta-Erythroidine | 3 | 2009 | 4 | 0.120 |
Why?
|
Endodeoxyribonucleases | 1 | 2014 | 44 | 0.120 |
Why?
|
Tanacetum parthenium | 1 | 2014 | 3 | 0.120 |
Why?
|
Deoxyribonuclease I | 1 | 2014 | 34 | 0.120 |
Why?
|
Drug Interactions | 6 | 2011 | 206 | 0.120 |
Why?
|
Nucleus Accumbens | 3 | 2013 | 21 | 0.120 |
Why?
|
G2 Phase | 1 | 2014 | 13 | 0.120 |
Why?
|
Thalamus | 2 | 2006 | 36 | 0.120 |
Why?
|
Neuralgia | 2 | 2012 | 62 | 0.120 |
Why?
|
Vascular Access Devices | 1 | 2014 | 23 | 0.120 |
Why?
|
Computer Simulation | 2 | 2013 | 282 | 0.120 |
Why?
|
Hematopoietic Stem Cells | 1 | 2015 | 184 | 0.120 |
Why?
|
Diet | 1 | 2018 | 564 | 0.120 |
Why?
|
Multienzyme Complexes | 1 | 2013 | 35 | 0.120 |
Why?
|
Viscosity | 2 | 2010 | 7 | 0.110 |
Why?
|
Dioxolanes | 1 | 2013 | 12 | 0.110 |
Why?
|
Swine, Miniature | 2 | 2010 | 16 | 0.110 |
Why?
|
Colorectal Neoplasms | 1 | 2016 | 234 | 0.110 |
Why?
|
Cyclin D1 | 2 | 2018 | 56 | 0.110 |
Why?
|
Indole Alkaloids | 1 | 2012 | 1 | 0.110 |
Why?
|
Apocynaceae | 1 | 2012 | 1 | 0.110 |
Why?
|
Cell Membrane | 3 | 2010 | 248 | 0.110 |
Why?
|
Sulfhydryl Compounds | 1 | 2012 | 14 | 0.110 |
Why?
|
Glucuronosyltransferase | 1 | 2014 | 126 | 0.110 |
Why?
|
Quality Assurance, Health Care | 1 | 2014 | 149 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2012 | 308 | 0.110 |
Why?
|
Pain Measurement | 4 | 2017 | 236 | 0.110 |
Why?
|
Transcriptome | 1 | 2015 | 313 | 0.110 |
Why?
|
Phytotherapy | 1 | 2012 | 44 | 0.110 |
Why?
|
Staphylococcal Infections | 1 | 2015 | 269 | 0.110 |
Why?
|
Polyamines | 1 | 2012 | 9 | 0.110 |
Why?
|
Intestines | 1 | 2014 | 176 | 0.110 |
Why?
|
Cytoskeletal Proteins | 1 | 2012 | 49 | 0.110 |
Why?
|
Disease Progression | 3 | 2013 | 822 | 0.100 |
Why?
|
Hyperglycemia | 1 | 2012 | 79 | 0.100 |
Why?
|
Amino Acids | 1 | 2014 | 358 | 0.100 |
Why?
|
Half-Life | 3 | 2007 | 84 | 0.100 |
Why?
|
Staphylococcus aureus | 1 | 2015 | 326 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 37 | 0.100 |
Why?
|
Alcoholism | 2 | 2012 | 232 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2013 | 73 | 0.100 |
Why?
|
Vincristine | 1 | 2012 | 89 | 0.100 |
Why?
|
Sulindac | 2 | 2013 | 2 | 0.100 |
Why?
|
Pain Threshold | 3 | 2018 | 46 | 0.100 |
Why?
|
Swine | 2 | 2010 | 391 | 0.100 |
Why?
|
Algorithms | 4 | 2009 | 616 | 0.100 |
Why?
|
Alkynes | 1 | 2011 | 5 | 0.100 |
Why?
|
Middle Aged | 6 | 2009 | 11997 | 0.100 |
Why?
|
Administration, Mucosal | 1 | 2011 | 1 | 0.100 |
Why?
|
Mucociliary Clearance | 1 | 2011 | 3 | 0.100 |
Why?
|
Indolizines | 1 | 2011 | 5 | 0.100 |
Why?
|
Plasma Membrane Neurotransmitter Transport Proteins | 2 | 2008 | 3 | 0.100 |
Why?
|
Norepinephrine | 2 | 2009 | 107 | 0.100 |
Why?
|
Chromones | 1 | 2011 | 21 | 0.100 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 166 | 0.100 |
Why?
|
Nerve Tissue Proteins | 3 | 2008 | 193 | 0.100 |
Why?
|
Gels | 1 | 2011 | 18 | 0.100 |
Why?
|
Administration, Intranasal | 1 | 2011 | 28 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2017 | 210 | 0.100 |
Why?
|
Libraries, Digital | 1 | 2011 | 2 | 0.100 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 4 | 2013 | 8 | 0.090 |
Why?
|
Adult | 6 | 2009 | 13160 | 0.090 |
Why?
|
Data Interpretation, Statistical | 4 | 2013 | 157 | 0.090 |
Why?
|
Enzyme Activation | 4 | 2014 | 276 | 0.090 |
Why?
|
Tetracycline | 1 | 2010 | 20 | 0.090 |
Why?
|
Benzopyrans | 1 | 2010 | 12 | 0.090 |
Why?
|
Tissue Distribution | 2 | 2010 | 164 | 0.090 |
Why?
|
Drug Therapy | 1 | 2011 | 46 | 0.090 |
Why?
|
Hydrogenation | 1 | 2010 | 2 | 0.090 |
Why?
|
Hydroquinones | 1 | 2010 | 3 | 0.090 |
Why?
|
Norbornanes | 1 | 2010 | 3 | 0.090 |
Why?
|
Plant Extracts | 1 | 2012 | 190 | 0.090 |
Why?
|
Proteins | 2 | 2023 | 341 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2010 | 77 | 0.090 |
Why?
|
Myeloablative Agonists | 1 | 2010 | 30 | 0.090 |
Why?
|
Diffusion | 5 | 2009 | 14 | 0.090 |
Why?
|
United States | 4 | 2008 | 4838 | 0.090 |
Why?
|
Blood Glucose | 1 | 2012 | 432 | 0.090 |
Why?
|
Microwaves | 1 | 2009 | 11 | 0.090 |
Why?
|
Acetates | 2 | 2007 | 49 | 0.090 |
Why?
|
Dextromethorphan | 1 | 2009 | 17 | 0.090 |
Why?
|
Urethane | 1 | 2009 | 6 | 0.090 |
Why?
|
Anti-Infective Agents | 1 | 2010 | 97 | 0.090 |
Why?
|
Glutamate-Cysteine Ligase | 2 | 2013 | 20 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2011 | 157 | 0.090 |
Why?
|
Kidney | 1 | 2014 | 665 | 0.090 |
Why?
|
Protein Disulfide Reductase (Glutathione) | 1 | 2009 | 2 | 0.090 |
Why?
|
Electrophysiology | 2 | 2008 | 78 | 0.080 |
Why?
|
Ventral Tegmental Area | 1 | 2009 | 7 | 0.080 |
Why?
|
Basal Ganglia | 1 | 2009 | 26 | 0.080 |
Why?
|
Proteinuria | 1 | 2009 | 39 | 0.080 |
Why?
|
Conditioning, Operant | 3 | 2018 | 116 | 0.080 |
Why?
|
Water | 1 | 2009 | 76 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2009 | 111 | 0.080 |
Why?
|
Cattle | 2 | 2007 | 210 | 0.080 |
Why?
|
Nociception | 2 | 2019 | 13 | 0.080 |
Why?
|
Aldehydes | 1 | 2009 | 83 | 0.080 |
Why?
|
Glass | 1 | 2008 | 3 | 0.080 |
Why?
|
Adsorption | 1 | 2008 | 17 | 0.080 |
Why?
|
Mutant Chimeric Proteins | 1 | 2008 | 1 | 0.080 |
Why?
|
Skin Physiological Phenomena | 1 | 2008 | 15 | 0.080 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 13 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2008 | 448 | 0.080 |
Why?
|
Surface Properties | 1 | 2008 | 72 | 0.080 |
Why?
|
Transcription Factors | 2 | 2009 | 563 | 0.080 |
Why?
|
Liver | 1 | 2014 | 1109 | 0.080 |
Why?
|
Maternal Exposure | 1 | 2008 | 86 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2008 | 48 | 0.080 |
Why?
|
Tromethamine | 1 | 2007 | 3 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2009 | 161 | 0.080 |
Why?
|
Combinatorial Chemistry Techniques | 1 | 2007 | 10 | 0.080 |
Why?
|
Aerosols | 1 | 2008 | 73 | 0.080 |
Why?
|
Thiazolidines | 1 | 2007 | 5 | 0.080 |
Why?
|
Biological Transport, Active | 2 | 2008 | 30 | 0.080 |
Why?
|
Hepatitis C | 1 | 2008 | 77 | 0.080 |
Why?
|
Guanidine | 1 | 2007 | 3 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 55 | 0.070 |
Why?
|
Hydrogen | 1 | 2007 | 13 | 0.070 |
Why?
|
Pregnanes | 1 | 2007 | 3 | 0.070 |
Why?
|
Allosteric Regulation | 3 | 2013 | 13 | 0.070 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2007 | 39 | 0.070 |
Why?
|
Semicarbazones | 1 | 2007 | 1 | 0.070 |
Why?
|
Seizures | 1 | 2009 | 196 | 0.070 |
Why?
|
Motion Sickness | 1 | 2007 | 8 | 0.070 |
Why?
|
PTEN Phosphohydrolase | 1 | 2007 | 55 | 0.070 |
Why?
|
Tablets | 1 | 2007 | 31 | 0.070 |
Why?
|
Calibration | 1 | 2007 | 58 | 0.070 |
Why?
|
Hippocampus | 1 | 2009 | 228 | 0.070 |
Why?
|
Membranes, Artificial | 2 | 2023 | 15 | 0.070 |
Why?
|
Oxidation-Reduction | 3 | 2013 | 319 | 0.070 |
Why?
|
Extracellular Fluid | 1 | 2006 | 15 | 0.070 |
Why?
|
Gene Transfer Techniques | 1 | 2007 | 37 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 595 | 0.070 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 62 | 0.070 |
Why?
|
Permeability | 4 | 2010 | 68 | 0.070 |
Why?
|
Hydrolysis | 1 | 2006 | 63 | 0.070 |
Why?
|
Xenopus laevis | 3 | 2013 | 38 | 0.070 |
Why?
|
Crystallography | 1 | 2006 | 6 | 0.070 |
Why?
|
Absorption | 1 | 2006 | 22 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2015 | 412 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2007 | 182 | 0.070 |
Why?
|
Random Allocation | 3 | 2013 | 280 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2009 | 373 | 0.070 |
Why?
|
Neostriatum | 3 | 2013 | 10 | 0.070 |
Why?
|
Cyclization | 1 | 2005 | 5 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2007 | 80 | 0.070 |
Why?
|
Cyclooxygenase 2 | 3 | 2013 | 45 | 0.070 |
Why?
|
Atenolol | 1 | 2005 | 13 | 0.070 |
Why?
|
Timolol | 1 | 2005 | 2 | 0.070 |
Why?
|
Plant Roots | 1 | 2005 | 34 | 0.070 |
Why?
|
Cells, Cultured | 4 | 2012 | 1571 | 0.070 |
Why?
|
Hyperthermia, Induced | 1 | 2007 | 118 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2010 | 1031 | 0.070 |
Why?
|
Synaptic Membranes | 1 | 2005 | 2 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2021 | 268 | 0.070 |
Why?
|
Carbonates | 1 | 2005 | 3 | 0.060 |
Why?
|
Formaldehyde | 3 | 2011 | 52 | 0.060 |
Why?
|
Constriction, Pathologic | 3 | 2011 | 94 | 0.060 |
Why?
|
Nitrosamines | 3 | 2011 | 9 | 0.060 |
Why?
|
Pregnancy | 2 | 2012 | 2584 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 162 | 0.060 |
Why?
|
Chickens | 1 | 2005 | 106 | 0.060 |
Why?
|
Butyrates | 1 | 2005 | 30 | 0.060 |
Why?
|
Program Evaluation | 2 | 2003 | 349 | 0.060 |
Why?
|
X-Rays | 2 | 2017 | 55 | 0.060 |
Why?
|
Valerates | 1 | 2005 | 34 | 0.060 |
Why?
|
Octanols | 1 | 2004 | 1 | 0.060 |
Why?
|
Transfection | 1 | 2005 | 357 | 0.060 |
Why?
|
Formates | 1 | 2004 | 4 | 0.060 |
Why?
|
Aged, 80 and over | 2 | 2009 | 3125 | 0.060 |
Why?
|
Physical Stimulation | 3 | 2008 | 35 | 0.060 |
Why?
|
Papilloma | 1 | 2004 | 9 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2005 | 378 | 0.060 |
Why?
|
Neuropeptides | 1 | 2004 | 37 | 0.060 |
Why?
|
Ubiquitin | 2 | 2015 | 45 | 0.060 |
Why?
|
Plants, Genetically Modified | 1 | 2004 | 22 | 0.060 |
Why?
|
Biological Assay | 1 | 2004 | 45 | 0.060 |
Why?
|
Patient Education as Topic | 2 | 2006 | 295 | 0.060 |
Why?
|
Carboxy-Lyases | 1 | 2003 | 2 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 245 | 0.060 |
Why?
|
Patient Care Team | 1 | 2006 | 255 | 0.060 |
Why?
|
Cost Control | 1 | 2003 | 13 | 0.060 |
Why?
|
Internationality | 1 | 2004 | 36 | 0.060 |
Why?
|
Mice, Transgenic | 2 | 2017 | 555 | 0.060 |
Why?
|
Ultrafiltration | 1 | 2023 | 7 | 0.060 |
Why?
|
Dialysis Solutions | 1 | 2023 | 3 | 0.060 |
Why?
|
Discrimination Learning | 2 | 2018 | 63 | 0.060 |
Why?
|
Yersinia pestis | 1 | 2003 | 18 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 66 | 0.060 |
Why?
|
Anticarcinogenic Agents | 1 | 2003 | 34 | 0.060 |
Why?
|
Drug Utilization | 1 | 2004 | 78 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2004 | 44 | 0.060 |
Why?
|
Sirolimus | 2 | 2016 | 62 | 0.060 |
Why?
|
Alkylation | 2 | 2019 | 11 | 0.060 |
Why?
|
Urea | 1 | 2023 | 77 | 0.060 |
Why?
|
Cost of Illness | 1 | 2004 | 117 | 0.060 |
Why?
|
Epidemiologic Studies | 1 | 2003 | 25 | 0.050 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2003 | 39 | 0.050 |
Why?
|
Insurance Coverage | 1 | 2004 | 102 | 0.050 |
Why?
|
Fibroblasts | 2 | 2015 | 343 | 0.050 |
Why?
|
Young Adult | 2 | 2009 | 3936 | 0.050 |
Why?
|
Carcinogens | 3 | 2011 | 199 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2004 | 273 | 0.050 |
Why?
|
Immunotoxins | 1 | 2002 | 6 | 0.050 |
Why?
|
Electric Stimulation | 2 | 2016 | 116 | 0.050 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2002 | 46 | 0.050 |
Why?
|
Radiation, Ionizing | 1 | 2003 | 100 | 0.050 |
Why?
|
Medicare | 1 | 2004 | 244 | 0.050 |
Why?
|
Chemical Phenomena | 2 | 2014 | 17 | 0.050 |
Why?
|
Spheroids, Cellular | 1 | 2021 | 25 | 0.050 |
Why?
|
Tissue Culture Techniques | 1 | 2021 | 40 | 0.050 |
Why?
|
Gamma Rays | 2 | 2015 | 49 | 0.050 |
Why?
|
Thioredoxins | 2 | 2013 | 24 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2002 | 172 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2008 | 2744 | 0.050 |
Why?
|
Forecasting | 1 | 2002 | 150 | 0.050 |
Why?
|
Cyclooxygenase 2 Inhibitors | 2 | 2013 | 19 | 0.050 |
Why?
|
Sumoylation | 1 | 2020 | 21 | 0.050 |
Why?
|
Amino Acid Sequence | 3 | 2008 | 587 | 0.050 |
Why?
|
Patch-Clamp Techniques | 2 | 2013 | 124 | 0.050 |
Why?
|
Aged | 3 | 2009 | 9272 | 0.050 |
Why?
|
Electrochemistry | 2 | 2013 | 26 | 0.050 |
Why?
|
Adolescent | 2 | 2009 | 6340 | 0.050 |
Why?
|
Catalytic Domain | 1 | 2020 | 57 | 0.050 |
Why?
|
Molecular Sequence Data | 3 | 2008 | 797 | 0.050 |
Why?
|
Densitometry | 1 | 2020 | 11 | 0.050 |
Why?
|
X-Ray Diffraction | 1 | 2020 | 10 | 0.050 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 18 | 0.050 |
Why?
|
Tensile Strength | 1 | 2020 | 28 | 0.050 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 36 | 0.040 |
Why?
|
Infant | 1 | 2008 | 3551 | 0.040 |
Why?
|
Pilot Projects | 1 | 2002 | 699 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2004 | 458 | 0.040 |
Why?
|
Cytokines | 2 | 2013 | 612 | 0.040 |
Why?
|
Catalepsy | 1 | 2019 | 9 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2013 | 971 | 0.040 |
Why?
|
Cell Movement | 2 | 2010 | 247 | 0.040 |
Why?
|
Cyclin A | 1 | 2018 | 6 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2004 | 487 | 0.040 |
Why?
|
Superoxide Dismutase | 2 | 2010 | 113 | 0.040 |
Why?
|
Mesocricetus | 2 | 2008 | 6 | 0.040 |
Why?
|
Cell Cycle Checkpoints | 1 | 2018 | 32 | 0.040 |
Why?
|
Ether-A-Go-Go Potassium Channels | 1 | 2018 | 5 | 0.040 |
Why?
|
Streptozocin | 1 | 2018 | 23 | 0.040 |
Why?
|
Postural Balance | 2 | 2008 | 56 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2008 | 57 | 0.040 |
Why?
|
Hepacivirus | 1 | 2018 | 103 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2010 | 269 | 0.040 |
Why?
|
Cyclohexanols | 1 | 2017 | 21 | 0.040 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2017 | 14 | 0.040 |
Why?
|
Reinforcement Schedule | 1 | 2018 | 78 | 0.040 |
Why?
|
Carrier Proteins | 2 | 2013 | 304 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 67 | 0.040 |
Why?
|
bcl-2-Associated X Protein | 1 | 2017 | 56 | 0.040 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2018 | 168 | 0.040 |
Why?
|
Cocaine | 2 | 2011 | 169 | 0.040 |
Why?
|
NADP | 1 | 2016 | 22 | 0.040 |
Why?
|
Prostate | 1 | 2017 | 117 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2016 | 11 | 0.030 |
Why?
|
Phosphoserine | 1 | 2016 | 6 | 0.030 |
Why?
|
Deoxyglucose | 1 | 2016 | 36 | 0.030 |
Why?
|
NF-kappa B p52 Subunit | 1 | 2016 | 6 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 129 | 0.030 |
Why?
|
Progesterone | 1 | 2016 | 57 | 0.030 |
Why?
|
Child | 1 | 2008 | 6824 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 106 | 0.030 |
Why?
|
Infusions, Intravenous | 2 | 2007 | 207 | 0.030 |
Why?
|
DNA | 2 | 2010 | 545 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2010 | 2910 | 0.030 |
Why?
|
Turtles | 1 | 2015 | 1 | 0.030 |
Why?
|
Cholinergic Antagonists | 1 | 2015 | 5 | 0.030 |
Why?
|
Centrosome | 1 | 2015 | 11 | 0.030 |
Why?
|
Bungarotoxins | 1 | 2015 | 6 | 0.030 |
Why?
|
Cholinergic Agonists | 1 | 2015 | 10 | 0.030 |
Why?
|
Rubidium | 2 | 2005 | 4 | 0.030 |
Why?
|
Virus Replication | 1 | 2016 | 140 | 0.030 |
Why?
|
Phenotype | 1 | 2018 | 727 | 0.030 |
Why?
|
Transition Temperature | 2 | 2005 | 6 | 0.030 |
Why?
|
Taxoids | 1 | 2014 | 37 | 0.030 |
Why?
|
Biotransformation | 2 | 2005 | 86 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 294 | 0.030 |
Why?
|
Up-Regulation | 1 | 2016 | 450 | 0.030 |
Why?
|
Drug Resistance | 1 | 2014 | 63 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 45 | 0.030 |
Why?
|
Drug Inverse Agonism | 1 | 2014 | 18 | 0.030 |
Why?
|
Protein Biosynthesis | 1 | 2016 | 253 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2015 | 184 | 0.030 |
Why?
|
Microsomes | 1 | 2014 | 35 | 0.030 |
Why?
|
Chromatin | 1 | 2015 | 152 | 0.030 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 375 | 0.030 |
Why?
|
Dopa Decarboxylase | 1 | 2013 | 2 | 0.030 |
Why?
|
Glutathione Peroxidase | 1 | 2013 | 23 | 0.030 |
Why?
|
Reserpine | 1 | 2013 | 13 | 0.030 |
Why?
|
Tyrosine 3-Monooxygenase | 1 | 2013 | 11 | 0.030 |
Why?
|
Dihydroxyphenylalanine | 1 | 2013 | 5 | 0.030 |
Why?
|
Animals, Genetically Modified | 1 | 2013 | 49 | 0.030 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2013 | 15 | 0.030 |
Why?
|
Microdialysis | 1 | 2013 | 18 | 0.030 |
Why?
|
Extracellular Space | 1 | 2013 | 38 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 15 | 0.030 |
Why?
|
Cytotoxins | 1 | 2013 | 16 | 0.030 |
Why?
|
Isoxazoles | 1 | 2013 | 14 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2013 | 66 | 0.030 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2013 | 15 | 0.030 |
Why?
|
Zebrafish | 1 | 2013 | 54 | 0.030 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2013 | 17 | 0.030 |
Why?
|
Neovascularization, Physiologic | 1 | 2013 | 67 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 71 | 0.030 |
Why?
|
Medicine, African Traditional | 1 | 2012 | 2 | 0.030 |
Why?
|
3T3-L1 Cells | 1 | 2012 | 13 | 0.030 |
Why?
|
bcl-X Protein | 1 | 2013 | 50 | 0.030 |
Why?
|
Seeds | 1 | 2012 | 25 | 0.030 |
Why?
|
Genes, p53 | 1 | 2013 | 51 | 0.030 |
Why?
|
NAD | 1 | 2012 | 43 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 66 | 0.030 |
Why?
|
Patents as Topic | 1 | 2012 | 8 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2013 | 90 | 0.030 |
Why?
|
Drug-Seeking Behavior | 1 | 2012 | 5 | 0.030 |
Why?
|
DNA Replication | 1 | 2013 | 151 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2013 | 170 | 0.030 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2012 | 90 | 0.030 |
Why?
|
Histones | 1 | 2014 | 315 | 0.030 |
Why?
|
Neurotransmitter Uptake Inhibitors | 1 | 2011 | 7 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2013 | 209 | 0.020 |
Why?
|
Food | 1 | 2011 | 71 | 0.020 |
Why?
|
Vero Cells | 1 | 2011 | 38 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2012 | 225 | 0.020 |
Why?
|
Calcium | 1 | 2013 | 397 | 0.020 |
Why?
|
Molecular Chaperones | 1 | 2011 | 64 | 0.020 |
Why?
|
Antioxidants | 1 | 2013 | 248 | 0.020 |
Why?
|
DNA Primers | 1 | 2011 | 206 | 0.020 |
Why?
|
Umbilical Veins | 1 | 2010 | 23 | 0.020 |
Why?
|
Rotarod Performance Test | 1 | 2010 | 6 | 0.020 |
Why?
|
Gram-Positive Bacteria | 1 | 2010 | 15 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 9 | 1 | 2010 | 2 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 215 | 0.020 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2010 | 18 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2010 | 22 | 0.020 |
Why?
|
Glucose | 1 | 2012 | 340 | 0.020 |
Why?
|
Choice Behavior | 1 | 2011 | 85 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2010 | 96 | 0.020 |
Why?
|
Gram-Negative Bacteria | 1 | 2010 | 34 | 0.020 |
Why?
|
Fungi | 1 | 2010 | 44 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2010 | 10 | 0.020 |
Why?
|
Mice, SCID | 1 | 2010 | 175 | 0.020 |
Why?
|
Caspase 3 | 1 | 2010 | 97 | 0.020 |
Why?
|
Cations | 1 | 2009 | 10 | 0.020 |
Why?
|
Gastrointestinal Motility | 1 | 2010 | 46 | 0.020 |
Why?
|
Catalase | 1 | 2010 | 67 | 0.020 |
Why?
|
Protein Transport | 1 | 2010 | 179 | 0.020 |
Why?
|
Base Sequence | 1 | 2011 | 650 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2010 | 100 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2010 | 158 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2011 | 374 | 0.020 |
Why?
|
Drug Partial Agonism | 1 | 2009 | 6 | 0.020 |
Why?
|
Proteomics | 1 | 2012 | 328 | 0.020 |
Why?
|
Cell Shape | 1 | 2009 | 20 | 0.020 |
Why?
|
Neurotransmitter Agents | 1 | 2009 | 34 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2010 | 112 | 0.020 |
Why?
|
Boronic Acids | 1 | 2010 | 182 | 0.020 |
Why?
|
Pyrazines | 1 | 2010 | 187 | 0.020 |
Why?
|
Diffusion Chambers, Culture | 1 | 2009 | 7 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 283 | 0.020 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2008 | 28 | 0.020 |
Why?
|
Chemokines, C | 1 | 2008 | 1 | 0.020 |
Why?
|
Mucins | 1 | 2008 | 6 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 1806 | 0.020 |
Why?
|
Stereotyped Behavior | 1 | 2008 | 17 | 0.020 |
Why?
|
Dinoprostone | 1 | 2008 | 53 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 57 | 0.020 |
Why?
|
Bone Marrow | 1 | 2010 | 362 | 0.020 |
Why?
|
Chemistry, Physical | 1 | 2008 | 6 | 0.020 |
Why?
|
Acute Disease | 1 | 2009 | 369 | 0.020 |
Why?
|
Skin Irritancy Tests | 1 | 2008 | 3 | 0.020 |
Why?
|
Prefrontal Cortex | 1 | 2008 | 82 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2008 | 189 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2010 | 339 | 0.020 |
Why?
|
Reaction Time | 1 | 2008 | 216 | 0.020 |
Why?
|
Hot Temperature | 1 | 2008 | 208 | 0.020 |
Why?
|
Alcohol-Related Disorders | 1 | 2008 | 44 | 0.020 |
Why?
|
Vitreous Body | 1 | 2007 | 19 | 0.020 |
Why?
|
Sucrose | 1 | 2007 | 26 | 0.020 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2007 | 26 | 0.020 |
Why?
|
Dogs | 1 | 2007 | 182 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 47 | 0.020 |
Why?
|
Insecticides | 1 | 2007 | 15 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2007 | 22 | 0.020 |
Why?
|
RNA | 1 | 2008 | 170 | 0.020 |
Why?
|
Static Electricity | 1 | 2006 | 21 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2007 | 68 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2010 | 1105 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 904 | 0.020 |
Why?
|
Mutation | 1 | 2013 | 1293 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2007 | 157 | 0.020 |
Why?
|
Amphetamine | 1 | 2006 | 38 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2009 | 342 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2006 | 146 | 0.020 |
Why?
|
Synaptic Transmission | 1 | 2007 | 88 | 0.020 |
Why?
|
Inflammation | 1 | 2010 | 604 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2007 | 202 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 376 | 0.020 |
Why?
|
Nomifensine | 1 | 2005 | 2 | 0.020 |
Why?
|
Solvents | 1 | 2005 | 29 | 0.020 |
Why?
|
Hemicholinium 3 | 1 | 2005 | 3 | 0.020 |
Why?
|
Catheters, Indwelling | 1 | 2006 | 58 | 0.020 |
Why?
|
Mineral Oil | 1 | 2005 | 4 | 0.020 |
Why?
|
Acetylation | 1 | 2005 | 99 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2006 | 68 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2006 | 565 | 0.020 |
Why?
|
Caproates | 1 | 2005 | 1 | 0.020 |
Why?
|
Catheterization | 1 | 2006 | 97 | 0.020 |
Why?
|
Species Specificity | 1 | 2005 | 193 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2007 | 477 | 0.020 |
Why?
|
Propionates | 1 | 2005 | 24 | 0.020 |
Why?
|
Paraquat | 1 | 2004 | 5 | 0.020 |
Why?
|
Parkinson Disease, Secondary | 1 | 2004 | 7 | 0.020 |
Why?
|
Teratogens | 1 | 2004 | 7 | 0.020 |
Why?
|
Abdomen | 1 | 2005 | 79 | 0.020 |
Why?
|
Calorimetry, Differential Scanning | 1 | 2004 | 7 | 0.020 |
Why?
|
Epidermis | 1 | 2004 | 26 | 0.020 |
Why?
|
Molecular Weight | 1 | 2004 | 84 | 0.020 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 1 | 2004 | 10 | 0.020 |
Why?
|
Rabies virus | 1 | 2004 | 4 | 0.010 |
Why?
|
Symporters | 1 | 2004 | 17 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2004 | 33 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 2004 | 35 | 0.010 |
Why?
|
omega-N-Methylarginine | 1 | 2003 | 3 | 0.010 |
Why?
|
Chromatography, Affinity | 1 | 2004 | 40 | 0.010 |
Why?
|
Catalysis | 1 | 2003 | 88 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2007 | 436 | 0.010 |
Why?
|
Lung | 1 | 2007 | 480 | 0.010 |
Why?
|
Membranes | 1 | 2003 | 17 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2004 | 122 | 0.010 |
Why?
|
Thrombosis | 1 | 2006 | 249 | 0.010 |
Why?
|
Perfusion | 1 | 2002 | 47 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2003 | 486 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2003 | 181 | 0.010 |
Why?
|
Primary Health Care | 1 | 2003 | 353 | 0.010 |
Why?
|